WELCOME TO ENABLE 

The ENABLE project was launched on February 2014 (end beg 2020) within IMI's 'New Drugs for Bad Bugs' (ND4BB) programme.

The ENABLE consortium is especifically working to advance the development of potential antibiotics against Gram-negative bacteria, such as Escherichia coli. The goal of the project is to develop attractive antimicrobial candidates for testing in the clinic, bringing the possibility of new antibiotics to treat Gram-negative infections one step closer to patients.

This collaborative project creates and manages a drug discovery engine for testing and optimising molecules that are still in the earlier stages of drug discovery but have the potential to become future drug candidates capable of treating resistant Gram-negative infections.

Get involved!

Open Call Process (Gram-negative anti-infective programme)

Benefit from ENABLE's drug discovery and development platform

Industry and research organisations with interesting molecules and programmes can join the ENABLE project as partners and work with a diverse range of experts in microbiology, pharmacology and chemistry to help advance their molecule through the drug development process until it is an attractive candidate for clinical testing. Programme owners retain full ownership of their molecules to ensure optimum future commercial development.

Since its launch in February 2014, ENABLE has received over 70 Expressions of Interest from EU-based organisations with anti-infective programmes who wish to become part of this pan-European project. Several programmes were selected by the ENABLE Portfolio Management Committee (PMC) to join the consortium. Novel applications can be submitted at any time.

To learn more about the way to submit your program through the Open Call Process, please click here.

Project goals by 2020

• Identication of three antibacterial lead programmes which are confirmed as having promising antimicrobial activity

• Identification of two antibacterial clinical candidate programmes for preclinical testing

• Processing of at least one programme into preclinical and phase 1 clinical studies

Further project information

Please download the full factsheet for the project below.